A number of other research analysts also recently commented on AGN. UBS AG reaffirmed a buy rating and set a $275.00 target price on shares of Allergan PLC. in a report on Monday, May 15th. Sanford C. Bernstein reaffirmed an outperform rating on shares of Allergan PLC. in a report on Thursday, May 25th. ValuEngine downgraded Allergan PLC. from a buy rating to a hold rating in a report on Friday, June 2nd. Cowen and Company set a $400.00 price target on Allergan PLC. and gave the stock a buy rating in a report on Thursday, June 8th. Finally, Mizuho cut their price target on Allergan PLC. from $275.00 to $267.00 and set a buy rating on the stock in a report on Friday, June 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $274.69.
Allergan PLC. (NYSE AGN) opened at 223.58 on Monday. The firm has a 50-day moving average price of $232.72 and a 200 day moving average price of $236.77. The firm has a market capitalization of $74.74 billion, a P/E ratio of 6.81 and a beta of 1.18. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter last year, the firm earned $3.35 EPS. Allergan PLC.’s quarterly revenue was up 8.8% on a year-over-year basis. Analysts forecast that Allergan PLC. will post $16.25 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.
Several hedge funds and other institutional investors have recently modified their holdings of AGN. Vanguard Group Inc. boosted its position in shares of Allergan PLC. by 2.2% in the second quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after buying an additional 482,220 shares during the period. Northern Trust Corp boosted its position in shares of Allergan PLC. by 8.8% in the second quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after buying an additional 364,722 shares during the period. Veritas Asset Management LLP acquired a new stake in shares of Allergan PLC. in the first quarter worth $761,339,000. Edgewood Management LLC boosted its position in shares of Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock worth $646,090,000 after buying an additional 178,055 shares during the period. Finally, Epoch Investment Partners Inc. boosted its position in shares of Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after buying an additional 73,081 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.